Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases

He describes the science behind Coya's combination therapies, and programs targeting ALS (currently in a phase 2 study), FTD, and Alzheimer's.

Episode metadata supplied by the publisher feed · Published Mar 27, 2026

Embed this episode

Attribution link and audio player

Ready to play

Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases

0:00 13:34

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 13 minutes long.

This episode was published on March 27, 2026.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!